Yes, I am not sure if she was brought in to check that box. But I am sure was brought with her background with that in mine. OTCMarkets lists two independent. NP also knew the standard rules of nasdaq in the CC friday. Most otc companies talk about the big uplist, when you know it is out of the realm of possibility. Here though, there are nasdaq companies with drugs not nearly as far along as leronlimab. It is doable really anytime they wanted, it just depended on how much they really wanted it. In 2018, they thought the price was too high to pay to match the requirements (rs and big cash raise). Now with drug approval getting closer, I get the feeling from these actions, NP believes they will have the requirements this year.